Whittier Trust Co. of Nevada Inc. Sells 2,704 Shares of Johnson & Johnson $JNJ

Whittier Trust Co. of Nevada Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 2.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 128,360 shares of the company’s stock after selling 2,704 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Johnson & Johnson were worth $26,287,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. United Bank increased its holdings in shares of Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after purchasing an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after purchasing an additional 692 shares in the last quarter. Wealth Group Ltd. increased its holdings in shares of Johnson & Johnson by 12.8% in the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after purchasing an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. increased its holdings in shares of Johnson & Johnson by 9.8% in the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after purchasing an additional 6,584 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Guggenheim raised its price target to $266 and reiterated a Buy after JNJ’s Q1 results, citing upside from the Icotyde program and model updates — a bullish analyst call that supports upside to the stock. Guggenheim Raises JNJ Target
• Positive Sentiment: Q1 beat-and-raise: J&J reported revenue of ~$24.1B and EPS above estimates, and raised FY guidance — results and guidance lift confidence in Innovative Medicines and MedTech execution. How to Play J&J Post Q1 Beat-and-Raise
• Positive Sentiment: New MedTech clinical data for the TECNIS PureSee IOL at ASCRS reinforces product adoption and supports MedTech valuation — a tangible commercial/clinical tailwind for that segment. MedTech Data Sparks Fresh Look
• Neutral Sentiment: Inclusion/flow signals: coverage noting JNJ’s positioning in Russell 1000 growth indexes could produce modest passive flows, but this is a gradual impact rather than an immediate price mover. Russell 1000 Growth Signals
• Neutral Sentiment: Dividend & investor interest: JNJ appears on lists of high‑dividend picks (Ray Dalio lists) and dividend‑income roundups, supporting demand from income investors but not an immediate catalyst. JNJ Among High Dividend Picks
• Neutral Sentiment: Analyst landscape: mixed/upward target revisions — median targets near $250 and several buy/overweight calls lift medium‑term sentiment but vary by firm. QuiverQuant Earnings Opinions
• Negative Sentiment: Significant insider selling: multiple senior executives sold shares in recent months (Quiver data), which can sap sentiment and create short‑term selling pressure despite company results. Insider Trading & Sentiment
• Negative Sentiment: Stelara LOE remains a multi‑quarter structural headwind referenced in commentary — while pipeline gains offset some impact, patent erosion risk is a longer‑term margin pressure for Innovative Medicines. Stelara LOE Discussion

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $230.51 on Tuesday. Johnson & Johnson has a 12-month low of $146.12 and a 12-month high of $251.71. The firm has a market capitalization of $555.21 billion, a price-to-earnings ratio of 26.65, a price-to-earnings-growth ratio of 2.29 and a beta of 0.34. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm has a fifty day moving average of $241.32 and a 200-day moving average of $217.78.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.75%. The firm’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.3%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is presently 60.12%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,251,310.02. The trade was a 4.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 30,142 shares of company stock worth $7,360,528 over the last ninety days. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research reports. Raymond James Financial raised their price target on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Freedom Capital lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Royal Bank Of Canada reissued an “outperform” rating and issued a $265.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 15th. Daiwa Securities Group lifted their target price on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a report on Thursday, April 16th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $252.48.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.